Oncolytics Biotech's All Planned Facilities For Part A Of REO 033 Trial Activated, Multiple Participants Admitted
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced continued clinical and operational progress in REO
Oncolytics Biotech finished opening all its test locations for a big drug trial. When a company hits its plan targets like this, it shows the project is moving forward on track.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.